Evotec, Halozyme

Halozyme bids for Evotec; BeiGene gets a new name
The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first Lyfgenia revenue and Leerink built up its M&A team.
JPMorgan thinks may take time for market to digest Halozyme bid for Evotec
After Halozyme Therapeutics (HALO) confirmed it has submitted a non-binding proposal to the boards of Evotec (EVO) to acquire Evotec for EUR
Halozyme Submits $2.11 Billion Acquisition Offer For Evotec
Halozyme Therapeutics (HALO) offered to acquire German drug maker Evotec (EVO) in a deal with an equity value of 2 billion euros ($2.11 billion). Halozyme submitted a non-binding proposal to Evotec's management and supervisory board to buy the company for 11 euros a share in cash,
Evotec gains on Halozyme's takeover pro­pos­al
Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The news caused Evotec's shares to rise 18% in Europe while Halozyme's stock dropped 4.
Evotec surges on Halozyme takeover interest
Evotec surged on Friday after Halozyme Therapeutics confirmed it had submitted a non-binding proposal to buy the German biotech for €11.00 per share in cash, or about €2bn.
Germany’s Evotec Gets Takeover Interest From Halozyme
Germany’s Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a deal that would value the German drug developer at €2 billion ($2.1 billion). Most Read from BloombergUnder Trump,
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid
Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to enhance its capabilities
Evotec jumps as Halozyme confirms takeover interest (updated)
Evotec stock surges 10% as Halozyme Therapeutics expresses takeover interest, sparking investor excitement and speculation in the market.
Halozyme interested in acquiring Evotec for $2.1B, Bloomberg says
Evotec (EVO) is attracting potential takeover interest from Halozyme Therapeutics (HALO), Eyk Henning of Bloomberg reports, citing people
Halozyme Therapeutics Bids to Acquire German Competitor Evotec
Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) The San Diego-based biopharmaceutical company on Thursday said it is proposing to acquire competitor Evotec for EUR11 per share,
Halozyme makes 2 billion euro buyout offer for drug developer Evotec
Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio. Halozyme intends to purchase all the shares of Evotec at 11 euros per share,
FierceBiotech11h
Halozyme offers $2B for Evotec to expand beyond delivery tech used by J&J and Roche
Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an ...
Halozyme’s Strategic Acquisition of Evotec: A Buy Rating for Future Growth and Profitability
Analyst Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...
Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports
German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.
SDxCentral19h
Halozyme Proposes €2 Billion Acquisition of Evotec at €11 Per Share
Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...